% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Apr 16, 2013 7:30 PM Flag

    CTC 3rd generation iChip platform significant improvement

    News release from Mass General Hospital dated 4/3/13...
    "The new system was able to process blood samples at the extremely rapid rate of 10 million cells per second, handling a tube of blood in less than an hour. Both the mode of sorting out tagged CTCs, called tumor-antigen-dependent, and the technique that depletes white blood cells, called tumor-antigen-independent, recovered more than 80 percent of tumor cells from different types of cancer that had been added to blood samples. Comparison of the antigen-dependent-mode CTC-iChip with existing commercial technology for processing blood samples from patients with prostate, breast, pancreatic, colorectal and lung cancer showed the CTC-iChip to be more sensitive at detecting low levels of CTCs."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "In the antigen-independent mode, the CTC-iChip successfully identified CTCs from several types of cancers that had lost or never had the epithelial marker, including triple-negative breast cancer and melanoma."

      Big improvement. This system is not dependent on specific antigen presentation in order to detect CTC's. If a particular cancer lacks the target antigen or CTC's have undergone mesenchymal transition, the existing CellSearch system will miss them. I see many uses for the CTC technology. Early cancer detection with a simple blood test, genetic typing without a biopsy, diagnosis of progression, use as a surrogate endpoint in clinical trials, when properly validated this is a very promising technology.

8.68+0.09(+1.05%)Jul 22 4:00 PMEDT